Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197416 · ClinicalTrials.gov registry record · Phase 3
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT02197416 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 214 participants.
The verdict
NCT02197416, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.
Interventions
- DRUG dabigatran etexilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2014-09-29 |
| Est. Completion | 2019-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197416
The ClinicalTrials.gov registry entry for NCT02197416 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dabigatran etexilate is the first listed.
NCT02197416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02197416 about?
NCT02197416 is a clinical study titled "Safety of Dabigatran Etexilate in Blood Clot Prevention in Children". This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.
What is the current status of trial NCT02197416?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2014-09-29. Estimated completion is 2019-11-19.
What interventions are being tested in trial NCT02197416?
The interventions under investigation include: dabigatran etexilate (DRUG).
Who is sponsoring clinical trial NCT02197416?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.